Recursion Pharmaceuticals: Can AI Turn Biology Into Medicines? - $RXRX

From Empor.top - The Stories of Top Companies · 01:06:49

Show by Empor.top

Recursion Pharmaceuticals was built on an ambitious idea: that machines could search vast libraries of cell images for clues to new medicines. Now a pharma partner has advanced one of its discoveries, and an early trial of REC-4881 has shown a promising signal in patients—evidence that the platform may be producing useful biology. But revenue remains lumpy and concentrated, losses are steep, and the cash clock is running. Recursion’s challenge is to turn early signs into repeatable results before shareholders are asked to fund the experiment again.---Subscribe to our newsletter on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7408775804387491842Follow us on X @emportop---Transcript - https://empor.top/us/RXRXI. The Drug Discovery Machine Meets Its Hardest TestII. A Cell-Painting Lab Becomes a Public CompanyIII. The Map, the Molecule and the Pharma PartnerIV. The $688 Million Bet on ExscientiaV. The Pipeline Gets Smaller as the Company Tries to Get More From Each DollarVI. REC-4881 Gives the Platform Its First Patient-Level TestVII. A Platform Without a Proven TollboothVIII. Khan Inherits the Integration and the Proof BurdenIX. The Cash Clock and the Share CountX. Analysis & Bear vs. Bull CaseXI. Business & Investing LessonsXII. EpilogueXIII. OutroReferences

More episodes of Empor.top - The Stories of Top Companies

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.